PET/CT imaging of mice inoculated with the cells of a PD-L1-positive NSCLC lesion from a patient who was treated with pembrolizumab and ipilimumab 7 months prior showed a low tumor-to-blood ratio (approx. 1.6) in the tumor. This evidence concerns the gene CD274 and neoplasm.